Authorities claim the medications originated from sources other than Ozempic's producer and lacked the medication's essential active substance.
CHICAGO - A healthcare professional from Chicago stands accused of administering bogus Ozempic, the widely used weight-reduction treatment.
What We Know
Government prosecutors allege that Sharon Christine Sackman supplied imitation Ozempic to three individuals in Chicago during 2023.
Court documents indicate that although the vials bore Ozempic branding, they were not produced by Novo Nordisk, the pharmaceutical firm responsible for the original drug, and omitted semaglutide, its primary active element.
Prosecutors explained that Sackman functioned as a licensed practical nurse at the moment of the distribution but lacked authorization to prescribe, provide, dispense, or sell Ozempic.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
She faces one accusation of circulating improperly labeled medications and three charges of issuing fake pharmaceuticals. Each offense could result in a maximum federal imprisonment term of one year.
During her appearance in a Chicago federal courtroom on Tuesday, she entered a not guilty plea.
Authorities mentioned that Sackman, aged 52, presently resides in Playa del Carmen, Mexico.
What's Next
A court session to review the case's progress is set for February 3.
Health tracking apps like Shotlee can assist users in monitoring medication authenticity and side effects during weight management journeys.